Biotech RadarJobs updated

COMPANY

Cardiff Oncology

HQ: San Diego, CA source · cardiffoncology.com ↗ · West Coast

Cardiff Oncology is listed on ClinicalTrials.gov as the lead sponsor of 7 studies; the most recently updated is “Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation” (Phase 2, active not recruiting), in Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation. From public records Source · Oct 12, 2026

Keywords: Oncology

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

$50.0MRaised (2 yrs)

Timeline

  1. Partnership Partnership / licensing announced Sep 14, 2026. Source: SEC filing. source ↗
  2. Raise Follow-on offering — Registered direct: $10M (total, as published), announced Jul 15, 2026. Source: SEC filing. source ↗
  3. Raise Follow-on offering — Registered direct: $40M (total, as published), announced Dec 10, 2024. Source: SEC filing. source ↗

Funding

Raised: $50.0M. Last 2 years.

Feedback